ArticleBMC microbiology2026
Characterization of the novel class A β-Lactamase gene bla
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundClass A serine β-lactamases are important enzymes that contribute to bacterial resistance to β-lactam antibiotics, especially in gram-negative bacilli (e.g., Enterobacteriaceae). These enzymes are highly diverse with many molecular variants, and some enzymes (such as SHV and TEM) can be used to extend the inactivation spectrum to the latest generation of cephalosporins by mutation. Consequently, the mechanisms of resistance to antimicrobial agents in bacteria and the clinical implications of antimicrobial resistance need to be more comprehensively studied.
methodsAnimal fecal samples were collected with sterile swabs, and individual colonies were isolated via the agar plate streaking method. The minimum inhibitory concentration (MIC) of the antimicrobial agent was tested by the standard agar dilution method. The complete bacterial genome sequence was obtained using the Illumina and PacBio sequencing platforms. Potential resistance genes were annotated according to the Comprehensive Antibiotic Resistance Database (CARD) and validated by molecular cloning. The β-lactamase KOB-1 was acquired by using the expression vector pCold I, after which the enzymatic kinetics were determined. The evolutionary relationships and genetic environments of the sequences associated with this resistance gene were analyzed via bioinformatics methods.
resultsA novel chromosomal class A β-lactamase gene, bla
conclusionThe identification of additional resistance genes aids in the elucidation of bacterial resistance mechanisms and application of effective clinical treatments for infections caused by pathogens carrying similar resistance genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.